Extension of territories for GoFigure®

RNS Number : 2793H

OptiBiotix Health PLC

24 March 2020

 

OptiBiotix Health plc

( "OptiBiotix" or the "Company")

Extension of territories for GoFigure®

with Extensor

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare,announces it has extended the territories of its original distribution agreements with Extensor Robert Buczek ("Extensor") to distribute OptiBiotix's own label GoFigure® consumer weight management products in Ukraine, Estonia, Lithuania, Latvia, Kazakhstan, Kyrgyzstan, Tajikistan, Uzbekistan, Turkmenistan, Armenia, Azerbaijan, Georgia, Belarus, Moldova and Russia.

Extensor is OptiBiotix's exclusive partner in Poland for distributing its GoFigure® product range (RNS: 22 May 2019) and SlimBiome® (RNS: 6 December 2019). The signing of an amendment to the agreement granting Extensor exclusive rights to distribute GoFigure® into additional territories highlights the positive evolution of the GoFigure® and SlimBiome® distribution agreements. The deal will create new commercial opportunities in new territories which may generate revenues with the commercialisation of the GoFigure® range on new online platforms such as Domo in Ukraine: https://domo.co.ua/search?string=Gofigure&category=all .

Dr. Fred Narbel,   Managing Director of OptiBiotix's prebiotics division , commented:  "We are very pleased to strengthen our partnership with Extensor to distribute our GoFigure® range beyond the Polish borders as they have proven to be a very reliable commercial partner and have recently placed additional orders for GoFigure® branded products to replenish their stocks. The signing of a territory extension amendment to the original agreement shows a positive evolution of the relationship and increases the global reach of our trademarks thus contributing to increasing the value of our portfolio of trademarks."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

OptiBiotix Health plc		www.optibiotix.com
Stephen O'Hara, Chief Executive		Contact via Walbrook below
Cairn Financial Advisers LLP (NOMAD)		Tel: [phone]
Liam Murray / Jo Turner / Ludovico Lazzaretti
finnCap (Broker)		Tel: [phone]
Geoff Nash / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)
goetzpartners securities Limited	Tel: [phone]
Ulrich Kinzel
Walbrook PR Ltd		Mob: [phone]
Anna Dunphy

About OptiBiotix - www.optibiotix.com  

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness. 

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

 

END

 

 

MSCBRGDXUGDDGGX